Education
About Us
Working with TipRanks
Follow Us
Noile-Immune Biotech Inc. (JP:4893)
:4893
RESEARCH TOOLSreports
Total Valuation
Noile-Immune Biotech Inc. has a market cap or net worth of ¥7.75B. The enterprise value is ¥23.48B.
Market Cap¥7.75B
Enterprise Value¥23.48B
Share Statistics
Noile-Immune Biotech Inc. has 43,276,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,276,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Noile-Immune Biotech Inc.’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -22.66%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-22.66%
Return on Capital Employed (ROCE)-0.23
Revenue Per Employee303.48K
Profits Per Employee-38.56M
Employee Count25
Asset Turnover<0.01
Inventory Turnover0.02
Valuation Ratios
The current PE Ratio of Noile-Immune Biotech Inc. is -7.63. Noile-Immune Biotech Inc.’s PEG ratio is 1.48.
PE Ratio-7.63
PS Ratio0.00
PB Ratio6.51
Price to Fair Value1.56
Price to FCF-261.30
Price to Operating Cash Flow-261.30
PEG Ratio1.48
Income Statement
In the last 12 months, Noile-Immune Biotech Inc. had revenue of 7.59M and earned -964.46M in profits. Earnings per share was -22.26.
Revenue7.59M
Gross Profit7.39M
Operating Income-1.07B
Pretax Income-962.03M
Net Income-964.46M
EBITDA-1.07B
Earnings Per Share (EPS)-22.26
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Noile-Immune Biotech Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.29
52-Week Price Change-14.07%
50-Day Moving Average161.94
200-Day Moving Average169.98
Relative Strength Index (RSI)51.75
Average Volume (3m)867.82K
Important Dates
Noile-Immune Biotech Inc. upcoming earnings date is Aug 8, 2025, TBA (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Noile-Immune Biotech Inc. as a current ratio of 68.77, with Debt / Equity ratio of 0.00%
Current Ratio68.77
Quick Ratio68.65
Debt to Market Cap0.00
Net Debt to EBITDA4.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Noile-Immune Biotech Inc. has paid 2.42M in taxes.
Income Tax2.42M
Effective Tax Rate>-0.01
Enterprise Valuation
Noile-Immune Biotech Inc. EV to EBITDA ratio is -2.52, with an EV/FCF ratio of -3.03.
EV to Sales354.63
EV to EBITDA-2.52
EV to Free Cash Flow-3.03
EV to Operating Cash Flow-3.03
Balance Sheet
Noile-Immune Biotech Inc. has ¥4.67B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -¥4.67B billion.
Cash & Marketable Securities¥4.67B
Total Debt¥0.00
Net Cash-¥4.67B
Net Cash Per Share-¥107.91
Tangible Book Value Per Share¥109.14
Margins
Gross margin is 98.87%, with operating margin of -14092.30%, and net profit margin of -12711.94%.
Gross Margin98.87%
Operating Margin-14092.30%
Pretax Margin-12680.04%
Net Profit Margin-12711.94%
EBITDA Margin-14092.29%
EBIT Margin-14092.29%
Analyst Forecast
The average price target for Noile-Immune Biotech Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-97.61%
EPS Growth Forecast14.80%